Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BetterLife Pharma Inc BETRF


Primary Symbol: C.BETR

Healthcare
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be... see more

Recent & Breaking News (CSE:BETR)

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001

GlobeNewswire January 18, 2022

Dr. Eleanor Fish, Advisory Board Member, Awarded Order of Canada

GlobeNewswire January 6, 2022

BetterLife’s (CSE:BETR) Altum Pharmaceuticals secures financing commitment

Brieanna McCutcheon  December 22, 2021

IIROC Trade Resumption - BETR

PR Newswire December 22, 2021

BetterLife's Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor!

GlobeNewswire December 22, 2021

IIROC Trading Halt - BETR

PR Newswire December 22, 2021

BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression

GlobeNewswire December 9, 2021

H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!

GlobeNewswire December 3, 2021

BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile

GlobeNewswire November 29, 2021

BetterLife (CSE:BETR) confirms non-hallucinogenic properties of TD-0148A

Julia Kennedy  November 16, 2021

BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property

GlobeNewswire November 16, 2021

Developing Psychedelic Medicine Beyond What We Already Know!

GlobeNewswire November 5, 2021

BetterLife Obtains TD-0148A In Vitro Pharmacology Data Confirming its Activity in Key Receptors Implicated in Depression and Neuropathic Pain

GlobeNewswire November 4, 2021

BetterLife Pharma: Invitation to the Benzinga Global Small Cap Conference

Newsfile October 25, 2021

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

PR Newswire October 18, 2021

Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2

GlobeNewswire October 12, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

PR Newswire October 11, 2021

BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies

GlobeNewswire September 29, 2021

BetterLife files patent for treatment of cluster headaches and related disorders

John Ballem  September 27, 2021

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

GlobeNewswire September 27, 2021